The Europe T cell therapy market was valued at US$ 699.24 million in 2022 and is expected to reach US$ 2,345.49 million by 2030; it is estimated to grow at a CAGR of 16.3% from 2022 to 2030.
Increasing Number of T-Cell Therapy Approvals Drives the Europe T Cell Therapy Market
Targeted treatment, faster and more efficient recovery, and reduced side effects are among the advantages of t cell therapy. Globally, cell therapies are widely adopted owing to the availability of various approvals. For instance,
In 2023: The European Commission has granted approval for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. A 4-1BB costimulatory domain found in CAR T-cell therapy augments the expansion and persistence of CAR T cells. Adults with high grade B-cell lymphoma (HGBCL), diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) who are refractory to first-line chemotherapy or who relapsed within a year of finishing treatment are eligible for this treatment.
In 2022: With approval from the European Committee for Medicinal Products for Human Use (CHMP), Ebvallo from Atara Biotherapeutics is set to become the world's first licensed allogeneic T-cell therapy.
In 2022: Kite, a Gilead Company, announced that Yescarta (axicabtagene ciloleucel) has been approved by the European Commission for the treatment of adult patients with high-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL) who are refractory to first-line chemotherapy or who relapse within a year of finishing it.
Thus, the increasing number of approvals for T-cell therapy is fueling the market growth.
Europe T Cell Therapy Market Overview
The European T-cell therapy market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Countries such as Germany and the UK are expected to be the largest contributors to the market in this region. The rising prevalence of hematologic malignancies and solid tumors and the subsequent rise in approval of T-cell therapy are the major factors driving the market growth in Europe.
According to National Health Service (NHS), ~800 people in the UK are diagnosed with acute lymphoblastic leukemia yearly, and ~ 5,500 people in England are diagnosed with B-cell lymphoma annually. Due to the prevalence of leukemia and lymphoma in the UK, people opt for T-cell therapy to treat these cancers. Owing to the awareness and positive results of T-cell therapies, NHS has struck deals with various companies, such as AstraZeneca, to expand access to personalized CAR T-cell therapies.
Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Europe T Cell Therapy Market Segmentation
The Europe T cell therapy market is segmented into modality, therapy type, indication, and country.
Based on modality, the Europe T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.
Based on therapy type, the Europe T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.
Based on indication, the Europe T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.
Based on country, the Europe T cell therapy market is segmented into Germany, UK, France, Italy, Spain, the Rest of Europe. Germany dominated the Europe T cell therapy market in 2022.
Bristol-Myers Squibb Co, Gilead Sciences Inc, Immunocore Holdings Plc, Innovent Biologics Inc, Janssen Global Services LLC, Legend Biotech Corp, and Novartis AG are some of the leading companies operating in the Europe T cell therapy market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 699.24 Million |
| Market Size by 2030 | US$ 2,345.49 Million |
| CAGR (2022 - 2030) | 16.3% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Modality
|
|
Regions and Countries Covered
|
|
| Europe | UK, Germany, France, Russia, Italy, Rest of Europe |
| Market leaders and key company profiles |
|
The Europe T Cell Therapy Market is valued at US$ 699.24 Million in 2022, it is projected to reach US$ 2,345.49 Million by 2030.
As per our report Europe T Cell Therapy Market, the market size is valued at US$ 699.24 Million in 2022, projecting it to reach US$ 2,345.49 Million by 2030. This translates to a CAGR of approximately 16.3% during the forecast period.
The Europe T Cell Therapy Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe T Cell Therapy Market report:
The Europe T Cell Therapy Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe T Cell Therapy Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe T Cell Therapy Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+1 646 791 7070
sales@businessmarketinsights.com
Get Free Sample For Europe T Cell Therapy Market
